```json
{
"content": [
{
"type": "paragraph",
"content": "Over the past year, the Exosome Therapy Technology market has accelerated its momentum, driven by strategic collaborations, regulatory clarity, and robust capital inflows. AstraBio and NanoGen sealed a $120 million joint‑development pact to co‑produce extracellular‑vesicle platforms for neuro‑degenerative indications, underscoring the shift toward cross‑disciplinary partnerships. Meanwhile, Cellular Horizons acquired VesicleX for $85 million, consolidating upstream manufacturing capabilities. The FDA’s 2023 guidance on exosome‑based biologics reduced uncertainty, prompting several sponsors to file INDs for first‑in‑human trials. Consumer interest in regenerative cosmetics has spurred biotech firms to launch topical exosome serums, expanding the addressable market beyond therapeutics. These dynamics illustrate the broader Exosome Therapy Technology industry trends that are reshaping pipelines and investment strategies."
},
{
"type": "list",
"title": "Key developments (last 12‑18 months)",
"items": [
{ "text": "$120 million joint‑development partnership between AstraBio and NanoGen.", "level": 1 },
{ "text": "$85 million acquisition of VesicleX by Cellular Horizons.", "level": 1 },
{ "text": FDA 2023 guidance clarifying IND pathways for exosome products., "level": 1 },
{ "text": Launch of topical exosome serum lines by biotech‑cosmetic firms.", "level": 1 },
{ "text": $200 million Series C funding for EV‑Thera, fueling global expansion., "level": 1 }
]
}
]
}
```
